Homemade Rod Holder Pontoon

successfully completed the Phase III of

laquinimod study ALLEGRO

in Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX Nordic: ACTI) announced today the results of the two-year phase III study of laquinimod ALLEGRO, an oral, once daily, investigational immunomodulatory treatment for relapsing forms of multiple sclerosis (MS) . These data will be presented as late-breaking research at the Meeting Annual American Academy of Neurology (AAN).

"We are thrilled with the results of ALLEGRO, demonstrating that laquinimod significantly delays the progression of disability, the main goal of treatment of MS. Given the efficacy data, safety and tolerability to date, laquinimod may file a promising treatment option for the MS community "

ALLEGRO In the study, laquinimod showed a statistically significant 23 percent reduction in annualized relapse rate.

"ALLEGRO Study results are exciting because they suggest that oral laquinimod is a novel therapeutic option that decreases the activity of MS security and progression of the disease," said lead researcher Professor Giancarlo Comi, Department Director Neurology and the Institute of Experimental Neurology at the University Greeting Vite, San Raffaele, Italy. "Other pre-clinical data presented at this meeting indicate that oral laquinimod has a new protection mechanism and action in the central nervous system to significantly reduce neurological damage leading to disease."

Laquinimod was safe and well tolerated, with no immunosuppressive effects. The overall frequency of adverse effects, including the incidence of infections, were similar to those observed in the placebo group. The most commonly reported adverse events were headache, nasopharyngitis and back pain. The incidence of elevated liver enzymes was higher in patients treated laquinimod, however, these elevations were transient, asymptomatic and reversible. No deaths were reported in patients treated with laquinimod.

ALLEGRO Positive results are supported by new preclinical data also presented at the AAN meeting, rather than establishing the mechanism of action (MOA) of laquinimod, which led to a reduction in axonal damage, the main determinant of permanent disability in MS clinic. Cuprizone model data, designed to investigate the effect on neurodegeneration independent from inflammation, demyelination and laquinimod shown to reduce axonal damage while preserving more myelin-producing cells. This unique effect suggests a direct reduction in damage to nerves in the central nervous system (CNS).

It was shown laquinimod to modulate brain-derived neurotrophic factor (BDNF) pathway, a key factor in maintaining axonal integrity.

"We are thrilled with the results of ALLEGRO, demonstrating that laquinimod significantly delays the progression of disability, the main goal of treatment of MS. Given the efficacy data, safety and tolerability to date, laquinimod may file a promising treatment option to the MS community, "said Professor Yitzhak Petersburg, Teva Group Vice President, Global Brand products.
laquinimod The second phase III study, BRAVO, is currently underway with results expected in the third quarter 2011. regulatory proposals are planned in the U.S. and the EU after the availability of results BRAVO.

Teva Pharmaceutical Industries Ltd. SOURCE